- Tous > Quality and Safety: Medicines > Quality Assurance
- Tous > WHO Prequalification of Medical Products > WHO-UNICEF-UN Project
- Mots-clés > data collection systems
- Mots-clés > drug quality assurance
- Mots-clés > medicine procurement
- Mots-clés > medicines quality - database
- Mots-clés > pharmaceutical quality control
- Mots-clés > prequalification of medicines
- Mots-clés > quality assurance - medicines
- Mots-clés > Quality Assurance of Pharmaceuticals
- Mots-clés > quality control
- Mots-clés > quality tests - medicines
(2014; 2 pages)
The availability of poor quality medicines has become an issue of public health concern. Such medicines can jeopardize patient safety, lead to treatment failure and to the development of drug resistance and represent a waste of financial resources.
The problem of poor quality medicines is particularly widespread and potentially more devastating in low-income countries. It is therefore extremely important to strengthen such countries’ capacity for quality assurance (QA) and quality control (QC) of medicines.
In addition to good QC, public, transparent access to reliable state, regional and global data on the quality of medicines is also a necessity. To fulfil this need, in 2011 the Promoting the Quality of Medicines (PQM) programme – funded by the United States Agency for International Development (USAID) and implemented by the United States Pharmacopeial Convention (USP) – introduced the Medicines Quality Database (MQDB).
Currently, the MQDB contains over 13 000 records of medicines collected and tested from 12 countries...